EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Harnessing the AI/ML in Drug and Biological Products Discovery and Development: The Regulatory Perspective

Fahimeh Mirakhori, Sarfaraz K Niazi iD

Pharmaceuticals · 03.01.2025 · 18 (1) · 47

DOI: 10.3390/ph18010047 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 03.01.2025. Verfasst von Fahimeh Mirakhori und 1 weiteren Autor:innen. Beteiligte Einrichtung: College of Natural and Mathematics Sciences, University of Maryland, Baltimore County (UMBC), USG, Rockville, MD 20850, USA. Die Arbeit wurde bisher 147-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Artificial Intelligence (AI) has the disruptive potential to transform patients’ lives via innovations in pharmaceutical sciences, drug development, clinical trials, and manufacturing. However, it presents significant challenges, ethical concerns, and risks across sectors and societies. AI’s rapid advancement has revealed regulatory gaps as existing public policies struggle to keep pace with the challenges posed by these emerging technologies. The term AI itself has become commonplace to argue that greater “human oversight” for “machine intelligence” is needed to harness the power of this revolutionary technology for both potential and risk management, and hence to call for more practical regulatory guidelines, harmonized frameworks, and effective policies to ensure safety, scalability, data privacy, and governance, transparency, and equitable treatment. In this review paper, we employ a holistic multidisciplinary lens to survey the current regulatory landscape with a synopsis of the FDA workshop perspectives on the use of AI in drug and biological product development. We discuss the promises of responsible data-driven AI, challenges and related practices adopted to overcome limitations, and our practical reflections on regulatory oversight. Finally, the paper outlines a path forward and future opportunities for lawful ethical AI. This review highlights the importance of risk-based regulatory oversight, including diverging regulatory views in the field, in reaching a consensus.

Schlagwörter

Stichwörter der Autor:innen

advanced manufacturing technology (AMT)advanced therapy medicinal product (ATMP)artificial intelligence (AI)biologicscell and gene therapy (CGT)drug product developmentethical considerationregulatory frameworks

Autor:innen und Institutionen

  • College of Natural and Mathematics Sciences, University of Maryland, Baltimore County (UMBC), USG, Rockville, MD 20850, USA.
  • College of Pharmacy, University of Illinois, Chicago, IL 60612, USA.

ORCID-Profile: Sarfaraz K Niazi

Zitieren

APA

Mirakhori, F., & Niazi, S. K. (2025). Harnessing the AI/ML in Drug and Biological Products Discovery and Development: The Regulatory Perspective. Pharmaceuticals, 18(1), 47. https://doi.org/10.3390/ph18010047

Vancouver

Mirakhori F, Niazi SK. Harnessing the AI/ML in Drug and Biological Products Discovery and Development: The Regulatory Perspective. Pharmaceuticals. 2025;18(1):47. doi:10.3390/ph18010047

BibTeX
@article{Mirakhori2025,
  author = {Mirakhori, Fahimeh and Niazi, Sarfaraz K},
  title = {Harnessing the AI/ML in Drug and Biological Products Discovery and Development: The Regulatory Perspective},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {1},
  pages = {47},
  doi = {10.3390/ph18010047}
}
Kostenlos starten →